首页 | 本学科首页   官方微博 | 高级检索  
检索        


Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
Authors:Amila Orucevic  John L Bell  Alison P McNabb  Robert E Heidel
Institution:1.Department of Internal Medicine II,University Hospital Tübingen,Tübingen,Germany;2.Cancer Immunology and Immunotherapy Center,Saint Savas Cancer Hospital,Athens,Greece;3.Pathology Department,Saint Savas Cancer Hospital,Athens,Greece;4.Histocompatibility & Immunogenetics Lab, Hellenic Cord Blood Bank- H&I Laboratory,Biomedical Research Foundation of the Academy of Athens,Athens,Greece;5.Institute of Cancer Sciences,The University of Manchester,Manchester,UK;6.School of Science and Technology, College of Arts and Science,Nottingham Trent University,Nottingham,UK;7.Department of Haematological Medicine, The Rayne Institute,King’s College London,London,UK
Abstract:

Purpose

Breast cancer is a leading cause of cancer deaths in women, but despite steady improvements in therapies, treatment is still suboptimal. Immunotherapy holds promise as a more effective therapy for breast cancer; supporting this, our prior study showed that patients possessing HER2-reactive CD8+ T cells in blood experience survival superior to patients without these cells. Here, we define a composite set of biomarkers that identify patients with T cell responses to tumour antigens.

Methods

We assessed T cell responses following in vitro stimulation with the HER2, MUC1 and SUR tumour-associated antigens (TAA) by flow cytometry and intracellular cytokine staining in 50 breast cancer patients. We also measured HLA type, serum cytokines, tumour-infiltrating leukocytes and blood leukocyte populations.

Results

We found few correlations between TAA-reactive T cells and HLA type, serum cytokines and tumour-infiltrating leukocytes, whereas blood leukocyte phenotypes broadly correlated with TAA responses. This showed monocytes, natural killer cells, dendritic cells and T cells to be inversely associated with both CD4+ and CD8+ T cells reactive to tumour antigens. Moreover, combining multiple parameters improved the accuracy in predicting patients with TAA-responsive T cells.

Conclusion

This study therefore defines composite immune profiles that identify patients responding to TAAs which may allow better personalisation of cancer therapies.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号